Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Biomarkers in Neuropsychiatry : A Primer / / Antonio L. Teixeira, Natalia P. Rocha, and Michael Berk, editors
| Biomarkers in Neuropsychiatry : A Primer / / Antonio L. Teixeira, Natalia P. Rocha, and Michael Berk, editors |
| Edizione | [First edition.] |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2023] |
| Descrizione fisica | 1 online resource (363 pages) |
| Disciplina | 616.8 |
| Soggetto topico |
Neuropsychiatry
Biochemical markers |
| ISBN | 3-031-43356-4 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Contents -- Biomarkers in Medicine and Psychiatry: An Overview -- 1 Biomarkers in Medicine: Brief Historical Background and Updated Concepts -- 2 Steps in the Development of a Candidate Biomarker -- 3 Biomarkers in Psychiatry -- 4 Clinical Use of Biomarkers in Psychiatry: It Is Time to Embrace the Change -- 5 Final Remarks -- References -- Genetic Biomarkers of Psychiatric Disorders -- 1 Introduction -- 2 Principles and Methods in Psychiatric Genetics -- 2.1 Genome-Wide Association Study (GWAS) -- 2.2 Polygenic Risk Scores -- 2.3 Epigenetics -- 3 Findings in Specific Disorders -- 3.1 Autism Spectrum Disorder -- 3.2 Bipolar Disorder -- 3.3 Schizophrenia -- 3.4 Suicide -- 3.5 Major Depressive Disorder -- 4 Clinical Applications of Genetic and Epigenetic Studies -- 4.1 Pharmacogenetics -- 4.2 Polygenic Risk Scores -- 5 Conclusions -- References -- Neurophysiological Biomarkers -- 1 Introduction -- 2 Methodological Strategies for Biomarker Identification and Development -- 2.1 Overview of Neurophysiological and Related Neuroimaging Methods -- 2.2 Brain Activation: A Framework for Developing Local-Field Biomarkers -- 2.3 Network Neuroscience: A Framework for Developing Network-Level Biomarkers -- 2.4 Brain Controllability Analysis: A Framework for Developing System-Level Biomarkers -- 3 Preclinical and Clinical Research to Inform Neurophysiological Biomarker Development for Neuropsychiatric Disorders -- 3.1 Depression -- 3.2 Alzheimer's Disease (AD) -- 3.3 Stroke -- 4 Conclusions -- References -- Structural Neuroimaging Biomarkers in Psychiatry -- 1 Introduction -- 2 Structural Neuroimaging: General and Historical Aspects -- 3 Structural Neuroimaging Candidate Biomarkers in Psychiatry: Current Status -- 3.1 Structural Neuroimaging Findings in Mental Disorders: Similarities and Specificities -- 3.2 High-Risk Population Studies.
4 Perspectives in Structural Neuroimaging Biomarkers in Psychiatry -- References -- Functional Neuroimaging Biomarkers -- 1 Introduction -- 2 What Would Constitute an fMRI-Based Biomarker? -- 3 Challenges: Why Don't We Have Biomarkers? -- 3.1 Diagnostic Challenges -- 3.2 Limitations of fMRI in Development of Biomarkers -- 3.3 Discussion of Challenges Applying T-fMRI to Psychiatric Symptoms/Conditions -- 3.4 Discussion of Efforts with rs-fMRI and Challenges -- 4 Neuropsychiatric Disorders: Current Progress -- 4.1 Catatonia -- 4.2 Dementia -- 4.3 Epilepsy -- 4.4 Multiple Sclerosis -- 4.5 Parkinson's Disease -- 4.6 Traumatic Brain Injury -- 5 Future Directions -- 6 Conclusion -- References -- PET Biomarkers in Psychiatry -- 1 Introduction to PET in Psychiatry -- 1.1 PET Background -- 1.2 Principles of Radiotracer -- 2 PET Radioligands in Alzheimer's Disease (AD) -- 2.1 Alzheimer's Disease -- 2.2 Aβ -- 2.3 Tau -- 2.4 Microglial Activation and Neuroinflammation -- 2.5 Neurodegeneration -- 2.6 Epigenetics -- 3 PET Biomarkers in Schizophrenia and Psychosis -- 3.1 Schizophrenia -- 3.2 Dopamine -- 3.3 Glutamate -- 3.4 Microglial Activation -- 4 PET Biomarkers in Major Depressive Disorder (MDD) -- 4.1 Major Depressive Disorder -- 4.2 Serotonin -- 4.3 Glucose Metabolism -- 4.4 Glutamate -- 4.5 Monoamine Oxidase and Neuroinflammation -- 5 PET Biomarkers in Bipolar Disorder (BD) -- 5.1 Bipolar Disorder -- 5.2 Glucose Metabolism -- 5.3 Therapeutic Response Markers -- 6 PET Biomarkers in Anxiety Disorders, Post-Traumatic Stress Disorder (PTSD), and Fear Dysregulation -- 7 PET Biomarkers in Substance Use Disorders -- 7.1 Substance Use Disorders -- 7.2 Mechanisms Underlying Patterns of Drug Use -- 7.3 Long-Term Neurochemical Changes in Substance Users -- 8 Challenges in Using PET Biomarkers -- 8.1 Introduction -- 8.2 Biomarker/Radiotracer Availability. 8.3 Transdiagnostic Approach -- 8.4 Study Constraints -- 9 Future Applications -- 10 Conclusion -- References -- Digital Markers of Mental Health Problems: Phenotyping Across Biological, Psychological, and Environmental Dimensions -- 1 Introduction -- 2 What Are Digital (Bio)Markers? -- 3 Ethical Issues and Acceptability of Digital Biomarkers -- 4 Sensors and Devices Used to Generate Digital Biomarkers -- 4.1 Sensors -- 4.2 Tracking Interactions with Devices -- 4.3 Implantable and Ingestible Devices -- 5 Applications of Digital Markers -- 5.1 Assessment of Patients in Clinical Care -- 5.2 Evaluation and Delivery of Mental Health Interventions -- 5.3 Population Mental Health and Psychopathology -- 5.4 Barriers to Implementation -- 6 Current Challenges and Future Directions -- References -- Staging Biomarkers in Psychiatry -- 1 Introduction -- 2 Staging of Bipolar Disorder -- 2.1 Neuroimaging -- 2.2 Inflammatory and Neurotrophic Biomarkers -- 3 Staging of Major Depressive Disorder -- 3.1 Inflammatory and Neurotrophic Biomarkers -- 3.2 Neuroimaging -- 4 Staging of Post-Traumatic Stress Disorder -- 4.1 Neuroimaging -- 4.2 Inflammatory Biomarkers -- 5 Schizophrenia -- 5.1 Inflammatory and Neurotrophic Biomarkers -- 5.1.1 Neuroimaging -- 6 Conclusion -- References -- Biomarkers of Delirium and Cognitive Impairment -- 1 Introduction -- 2 Candidate Biomarkers -- 2.1 Inflammatory Biomarkers -- 2.2 Neuroendocrine Biomarkers -- 2.3 Biomarkers of Neurodegenerative Diseases and Delirium -- 2.4 Neurotransmitter Activity -- 2.5 Behavioral Biomarkers and Risk Assessment -- 2.6 Neuroimaging Biomarkers -- 2.7 Electroencephalogram (EEG) -- 3 Conclusion -- References -- Fluid-Based Biomarkers of Alzheimer's Disease -- 1 Introduction -- 2 Cerebrospinal Fluid (CSF) Markers of Alzheimer's Disease -- 3 Blood-Based Biomarkers of Alzheimer's Disease -- 4 Final Remarks. References -- Neuroimaging Biomarkers in Alzheimer's Disease and Related Disorders -- 1 Introduction -- 2 Neuroimaging Biomarkers -- 2.1 MRI Regional Brain Volume -- 2.2 Metabolism -- 2.3 Perfusion Imaging -- 2.4 Amyloid Imaging -- 2.5 Tau Imaging -- 2.6 Inflammation Imaging -- References -- Biomarkers of Cognitive Decline and Dementia in Down Syndrome -- 1 Introduction -- 2 Cognitive Markers -- 3 Biomarkers of Amyloid Pathology -- 3.1 CSF and Plasma Markers -- 3.2 Neuroimaging -- 4 Biomarkers of Tau Pathology -- 4.1 CSF and Plasma Markers -- 4.2 Neuroimaging -- 5 Biomarkers of Neurodegeneration -- 5.1 CSF and Plasma Markers -- 5.2 Neuroimaging -- 6 Biomarkers of Inflammation and Oxidative Stress -- 7 Biomarkers of Cerebrovascular Disease -- 8 Genes and Protein Expression -- 8.1 Amyloid Precursor Protein (APP) Gene -- 8.2 Apolipoprotein E (ApoE) -- 9 Conclusion -- References -- Biomarkers of Schizophrenia -- 1 Introduction -- 2 Genetic Biomarkers -- 3 Neuroimaging Biomarkers -- 3.1 Predictors for Transition to Psychosis -- 3.2 Diagnosis -- 3.3 Treatment Response -- 4 Peripheral Markers -- 4.1 Immune Markers -- 4.2 Oxidative Stress -- 5 Cognitive Markers -- 6 Discussion -- References -- Biomarkers for Bipolar Disorder -- 1 Introduction -- 2 Neuroimaging -- 3 Genetics -- 4 Peripheral Markers -- 4.1 HPA Axis Markers -- 4.2 Neurotrophic Markers -- 4.3 Immune Markers -- 4.4 Oxidative Stress -- 4.5 Metabolic Markers -- 5 Cognitive Markers -- 6 Circadian Markers -- 7 Discussion -- References -- Biomarkers in Anxiety Disorders -- 1 Introduction -- 2 Generalized Anxiety Disorder -- 2.1 Structural Brain Morphology - Structural Magnetic Resonance Imaging Studies in Generalized Anxiety Disorder -- 2.2 Structural Brain Morphology - in Generalized Anxiety Disorder -- 2.3 fMRI in Generalized Anxiety Disorder -- 2.3.1 Resting-State fMRI. 2.3.2 Emotional Dysregulation fMRI -- 2.3.3 Emotional Reactivity - Facial Affect and Image Processing -- 2.3.4 Emotional Reactivity - Verbal and Imagery Stimulus -- 2.3.5 Cognition and Emotion -- 2.3.6 Treatment Studies -- 2.4 Neurochemical Biomarkers in Generalized Anxiety Disorder -- 3 Panic Disorder -- 3.1 Structural Brain Morphology - Structural Magnetic Resonance Imaging Studies in Panic Disorder -- 3.2 Structural Brain Morphology - in Panic Disorder -- 3.3 fMRI in Panic Disorder -- 3.3.1 Resting-State fMRI in PD -- 3.3.2 Emotional Processing fMRI in PD -- 3.3.3 Treatment fMRI Studies -- 3.4 Physiological Biomarkers -- 3.4.1 Respiratory Patterns and Carbon Dioxide (CO2) Sensitivity -- 3.4.2 Heart Rate Variability -- 3.5 Neurochemical Biomarkers in PD -- 4 Social Anxiety Disorder -- 4.1 Structural Brain Morphology - Structural Magnetic Resonance Imaging Studies in Social Anxiety Disorder -- 4.2 Structural Brain Morphology - White Matter (WM) and Structural Connectivity - Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) in Social Anxiety Disorder -- 4.3 fMRI in Social Anxiety Disorder -- 4.3.1 Resting-State fMRI in SAD -- 4.3.2 Task-Based fMRI in SAD -- 4.3.3 Treatment fMRI Studies -- 4.4 PET and SPECT in Social Anxiety Disorder -- 4.5 Neurochemical Biomarkers in Social Anxiety Disorder -- 5 Final Considerations -- References -- Biomarkers in Obsessive-Compulsive Spectrum Disorders -- 1 Introduction -- 2 Neuroimaging Biomarkers -- 2.1 OCD Diagnosis -- 2.2 OCD Treatment Response -- 2.3 Obsessive-Compulsive Spectrum Disorders -- 3 Neuroinflammatory Biomarkers -- 4 Discussion -- References -- Sleep Disorders: Identifying Biomarkers and Clinical Applications -- 1 Introduction -- 2 What We Are Looking For -- 3 Where We Are -- 3.1 Sleep Disorders and Insufficient Sleep -- 3.2 Sleep Loss and Excessive Daytime Sleepiness. 3.3 Obstructive Sleep Apnea. |
| Record Nr. | UNINA-9910768197903321 |
| Cham, Switzerland : , : Springer, , [2023] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Social Media and Social Order / / ed. by David Herbert, Stefan Fisher-Høyrem
| Social Media and Social Order / / ed. by David Herbert, Stefan Fisher-Høyrem |
| Autore | Herbert David |
| Pubbl/distr/stampa | Berlin/Boston, : De Gruyter, 2022 |
| Descrizione fisica | 1 online resource (149 p.) |
| Disciplina | 302.231 |
| Soggetto topico | SOCIAL SCIENCE / Media Studies |
| Soggetto non controllato |
computational social science
digital media influence inter-group relations mass communication populism propaganda public interest social construction social interaction social media social network analysis, social networks social order technology |
| ISBN |
83-66675-61-0
3-11-076040-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Frontmatter -- Contents -- Acknowledgements -- 1 Introduction: How Do Social Media Change Social Order? The Deep Datafication of Society from Global to Local Scales (and Back Again) -- 2 The Social Construction of Reality - Really! -- 3 The Dramaturgy of Social Media: Platform Ecology, Uneven Networks, and the Myth of the Self -- 4 Clusters of Prestige: Social Media and Social Order in the Norwegian Bible Belt -- 5 Meme Collectives and Preferred Truths in Assam -- 6 Insurgent Ways of Looking: Gendering the Witness and the Land in the Visuality of Israel-Palestine -- 7 Gender and Race in the Digital Town Hall: Identity-Based Attacks Against US Legislators on Twitter -- 8 Participatory Propaganda: The Engagement of Audiences in the Spread of Persuasive Communications -- List of Figures -- List of Tables |
| Record Nr. | UNINA-9910557866703321 |
Herbert David
|
||
| Berlin/Boston, : De Gruyter, 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Social Media and Social Order / / ed. by David Herbert, Stefan Fisher-Høyrem
| Social Media and Social Order / / ed. by David Herbert, Stefan Fisher-Høyrem |
| Autore | Herbert David |
| Pubbl/distr/stampa | Berlin/Boston, : De Gruyter, 2022 |
| Descrizione fisica | 1 online resource (149 p.) |
| Disciplina | 302.231 |
| Soggetto topico | SOCIAL SCIENCE / Media Studies |
| Soggetto non controllato |
computational social science
digital media influence inter-group relations mass communication populism propaganda public interest social construction social interaction social media social network analysis, social networks social order technology |
| ISBN |
83-66675-61-0
3-11-076040-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Frontmatter -- Contents -- Acknowledgements -- 1 Introduction: How Do Social Media Change Social Order? The Deep Datafication of Society from Global to Local Scales (and Back Again) -- 2 The Social Construction of Reality - Really! -- 3 The Dramaturgy of Social Media: Platform Ecology, Uneven Networks, and the Myth of the Self -- 4 Clusters of Prestige: Social Media and Social Order in the Norwegian Bible Belt -- 5 Meme Collectives and Preferred Truths in Assam -- 6 Insurgent Ways of Looking: Gendering the Witness and the Land in the Visuality of Israel-Palestine -- 7 Gender and Race in the Digital Town Hall: Identity-Based Attacks Against US Legislators on Twitter -- 8 Participatory Propaganda: The Engagement of Audiences in the Spread of Persuasive Communications -- List of Figures -- List of Tables |
| Record Nr. | UNISA-996463250603316 |
|
Herbert David
|
||
| Berlin/Boston, : De Gruyter, 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
The Therapeutic Use of N-Acetylcysteine (NAC) in Medicine / / edited by Richard Eugene Frye, Michael Berk
| The Therapeutic Use of N-Acetylcysteine (NAC) in Medicine / / edited by Richard Eugene Frye, Michael Berk |
| Edizione | [1st ed. 2019.] |
| Pubbl/distr/stampa | Singapore : , : Springer Singapore : , : Imprint : Adis, , 2019 |
| Descrizione fisica | 1 online resource (392 pages) |
| Disciplina | 615.19 |
| Soggetto topico |
Pharmacotherapy
Pharmacology Pharmacology/Toxicology |
| ISBN | 981-10-5311-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1. History of N-acetylcysteine -- Part I. The Basic Science of NAC -- 2. Neurotransmitter Systems: glutamate -- 3. Neurotransmitter Systems: Dopamine -- 4. Oxidative Stress in Psychiatric Disorders -- 5. Mitochondrial Metabolism -- 6. Apoptosis -- 7. Inflammation -- Part II. The Clinical Use of NAC -- 8. Clinical Trials on N-Acetylcysteine -- 9. N-Acetylcysteine in the Poisoned Patient -- 10. The use of NAC as a Chelator for Metal Toxicity -- 11. Application of N-Acetylcysteine in Neurological Disorders -- 12. Application of N-Acetylcysteine in Psychiatric Disorders -- 13. Clinical Treatment of Addictive Disorders with N-Acetylcysteine -- 14. The Clinical Use of N-Acetylcysteine for the Treatment and Protection Against Renal Disease -- 15. Application of N-Acetylcysteine in Pulmonary Disorders -- 16. The Clinical Use of N-Acetylcysteine in Cardiology -- 17. The Clinical Use of N-acetylcysteine in Gastrointestinal Disorders -- 18. The Clinical Use of N-Acetylcysteine in Other Medical Disorders -- 19. The Physiological Effects of N-Acetylcysteine in Clinical Studies -- 20. Cysteine/Glutathione Deficiency: A Significant and Treatable Corollary of Disease -- 21. Pharmacology, Formulations and Adverse Effects. |
| Record Nr. | UNINA-9910337502603321 |
| Singapore : , : Springer Singapore : , : Imprint : Adis, , 2019 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||